SCHEMBL4655463

SCHEMBL4655463

CCN(O)C(CCC(=O)O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
TET2 Q6N021 3/20 0.41
KDM4A O75164 2/20 0.41
KDM4C Q9H3R0 2/20 0.41
KDM2A Q9Y2K7 2/20 0.41
TET3 O43151 1/20 0.41
FOLH1 Q04609 9/20 0.40
GABRP O00591 2/20 0.40
GABRD O14764 2/20 0.40
GABRA1 P14867 2/20 0.40
GABRB1 P18505 2/20 0.40
GABRG2 P18507 2/20 0.40
GABRB3 P28472 2/20 0.40
GABRA5 P31644 2/20 0.40
GABRA3 P34903 2/20 0.40
GABRA2 P47869 2/20 0.40
GABRB2 P47870 2/20 0.40
GABRA4 P48169 2/20 0.40
GABRE P78334 2/20 0.40
GABRA6 Q16445 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7701636 1.00 CYP1A2 (0.45) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL1221384 0.84 ALOX15 (0.45) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL3335954 0.84 ALOX15 (0.45) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL2639593 0.84 CYP1A2 (0.42) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL1286830 0.84 CYP1A2 (0.42) CYP1A2TET2KDM4AKDM4CKDM2A
D-Glutamate SCHEMBL8219041 0.84 ALOX15 (0.56) CYP1A2FOLH1GABRPGABRDGABRA1
SCHEMBL6992803 0.81 CYP1A2 (0.46) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL6311082 0.81 CYP1A2 (0.46) CYP1A2TET2KDM4AKDM4CKDM2A
SCHEMBL313183 0.79 FOLH1 (0.36) FOLH1GRIK1SLC1A3SLC1A2SLC1A1
Hydrochloric Acid SCHEMBL573426 0.79 CYP1A2 (0.45) CYP1A2TET2KDM4AKDM4CKDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106132456-B Apparatus, solution and method for sample collection 阿波根有限公司 2019-12-24 CN disclosed
EP-1392755-B1 LIPID-POLYMER-CONJUGATES COMPOSITIONS ASTELLAS PHARMA EUROP B V (NL) 2008-12-03 EP disclosed
US-20040241222-A1 Lipid-polymer-conjugates compositions ASTELLAS PHARMA EUROPE B.V. (NL) 2004-12-02 US disclosed
EP-1392755-A1 LIPID-POLYMER-CONJUGATES COMPOSITIONS YAMANOUCHI EUROPE B.V. (NL) 2004-03-03 EP disclosed
WO-2002098952-A1 LIPID-POLYMER-CONJUGATES COMPOSITIONS YAMANOUCHI EUROPE B.V. (NL) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040241222-A1 Lipid-polymer-conjugates compositions PHOSPHO1, PARG, GLUL CYP1A2 4418/4885TET2 3860/4885KDM4A 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.